Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Generally healthy, postmenopausal women, aged 40 to less than 65 years~* Intact uterus~* At least 12 months of spontaneous amenorrhea, OR 6 months spontaneous amenorrhea with follicle-stimulating hormone (FSH) levels \> 40 mIU/mL.~Exclusion Criteria:~* Use of oral estrogen-, progestin-, androgen-, or SERM-containing drug products within 8 weeks before screening (12 weeks for the osteoporosis substudy)~* A history or active presence of clinically important medical disease~* Malabsorption disorders

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): BZA 20mg/CE 0.625
- Arm 2 (Type: EXPERIMENTAL): BZA 20mg/CE 0.45
- Arm 3 (Type: ACTIVE_COMPARATOR): CE 0.45mg/MPA1.5mg
- Arm 4 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).